Novo Nordisk Pays $1.80bn To Buy Emisphere
Acquires Technology Used For Diabetes Pill Rybelsus
Executive Summary
The Danish major will develop the US firm's technology and use it on current and future pipeline assets with the aim of making more biologics orally available.
You may also be interested in...
Brand Spotlight: Novo Nordisk’s Semaglutide
Novo Nordisk’s semaglutide, a GLP-1 agonist marketed in an injected formulation as Ozempic, and an oral tablet form as Rybelsus, is a success story with the potential for an epic third act. First approved as a treatment for type 2 diabetes, semaglutide is under FDA review as a treatment for obesity, with additional clinical programs in NASH and Alzheimer’s disease.
Novo Nordisk Eyes Residual CV Risk In Atherosclerosis With Ziltivekimab
With GLP-1 sales increasing by 31% in the third quarter, Novo Nordisk has raised its sales and operating profit outlooks for 2020 to 5-8% at CER, and has outlined promising R&D progress against atherosclerosis and obesity.
Novo’s Rybelsus Pill Set To Disrupt Europe’s Diabetes Market
Rybelsus, the first oral GLP-1 treatment for type 2 diabetes, will likely secure EU approval in a couple of months.